Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Johnson & Johnson ( (JNJ) ) just unveiled an announcement.
At its 2026 Annual Meeting of Shareholders held on April 23, 2026, Johnson & Johnson investors elected all 12 director nominees to the board and approved, on an advisory basis, the company’s executive compensation framework and named executive officer pay. Shareholders also ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal 2026 but rejected a shareholder proposal to require an independent board chair, signaling continued support for the current governance and leadership structure.
The voting results showed strong backing for the board slate and say-on-pay resolution, indicating broad investor confidence in Johnson & Johnson’s strategic direction and management oversight. The defeat of the independent chair proposal preserves the existing board leadership configuration, which may influence future governance debates while maintaining continuity in oversight as the company executes its long-term healthcare strategy.
The most recent analyst rating on (JNJ) stock is a Buy with a $285.00 price target. To see the full list of analyst forecasts on Johnson & Johnson stock, see the JNJ Stock Forecast page.
Spark’s Take on JNJ Stock
According to Spark, TipRanks’ AI Analyst, JNJ is a Neutral.
The score is driven mainly by strong underlying financial performance and a supportive earnings outlook with raised guidance, tempered by clear near-term technical weakness and a relatively high P/E. Dividend yield provides some valuation support, but cash-flow/margin volatility and current bearish momentum keep the overall score in the upper-middle range.
To see Spark’s full report on JNJ stock, click here.
More about Johnson & Johnson
Johnson & Johnson is a global healthcare company operating across pharmaceuticals, medical devices, and consumer health products. It focuses on developing and manufacturing medicines, surgical technologies, and health-related products for patients, healthcare providers, and consumers worldwide, positioning itself as a diversified leader in the healthcare industry.
Average Trading Volume: 8,360,092
Technical Sentiment Signal: Buy
Current Market Cap: $547.6B
Learn more about JNJ stock on TipRanks’ Stock Analysis page.